Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0601 Phase II in non-inhibitor hemophilia A/B
CTR20222897Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bemiltenase alfa in hemophilia A, hemophilia B (HB), sponsored by Staidson Biopharmaceutical. Started Nov 2022; status: completed.
02
Drugs
bemiltenase alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20222897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222897.